The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 June 2026•

2 min read

FDA Grants Accelerated Approval to Sanofi’s Tzield for Type 1 Diabetes

Key Facts

1Sanofi's Tzield received FDA approval as the first disease-modifying therapy for patients recently diagnosed with Stage 3 Type 1 diabetes.

In a move reflecting the ongoing advancement in specialized biologic therapies, Sanofi's Tzield has received FDA approval as the first disease-modifying therapy for patients recently diagnosed with Stage 3 Type 1 diabetes. This accelerated approval is specifically indicated to slow the decline of endogenous insulin production in children and adolescents aged 8 to 17. The regulatory decision was supported by findings from the Phase 3 PROTECT study and supplemental data from a global clinical program involving more than 900 patients.

This approval strengthens Sanofi's position in the general medicines sector, where it competes with giants like Eli Lilly and Novo Nordisk in the global diabetes market. Per market data, Sanofi (SAN.PA) shares closed at 76.59 EUR on June 12, 2026, having traded between a low of 75.56 EUR and a high of 76.89 EUR during the session. Analysts note that Tzield provides Sanofi with a unique competitive edge as the only therapy currently approved to delay the progression of Stage 3 Type 1 diabetes.

Investors should watch for technical support at 75.56 EUR and resistance at 76.89 EUR based on the close at June 12, 2026. Looking ahead, the primary catalyst will be further clinical data required to transition this accelerated approval into a full regulatory nod. Additionally, broader market sentiment in the healthcare sector may be influenced by upcoming global inflation data from China and the US scheduled for the coming week.